|
1
|
Chan TC, Shiue YL and Li CF: The
biological impacts of CEBPD on urothelial carcinoma development and
progression. Front Oncol. 13:11237762023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
You X, Zhu C, Yu P, Wang X, Wang Y, Wang
J, Yu J and Wang K: Emerging strategy for the treatment of
urothelial carcinoma: Advances in antibody-drug conjugates
combination therapy. Biomed Pharmacother. 171:1161522024.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Szarvas T, Módos O, Horváth A and Nyirády
P: Why are upper tract urothelial carcinoma two different diseases?
Transl Androl Urol. 5:636–647. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gandhi J, Chen JF and Al-Ahmadie H:
Urothelial carcinoma: Divergent differentiation and morphologic
subtypes. Surg Pathol Clin. 15:641–659. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rayn KN, Hale GR, Bloom JB, Gold SA,
Carvalho FLF, Mehralivand S, Czarniecki M, Wood BJ, Merino MJ,
Choyke P, et al: Incidental bladder cancers found on
multiparametric MRI of the prostate gland: A single center
experience. Diagn Interv Radiol. 24:316–320. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bu K, Shi Z, Lu Y, Zhao J and Li B: An
occult urothelial carcinoma with wide multiorgan metastases and its
genetic alteration profiling: Case report and literature review.
Medicine (Baltimore). 98:e152452019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alghadir AH, Anwer S, Iqbal A and Iqbal
ZA: Test-retest reliability, validity, and minimum detectable
change of visual analog, numerical rating, and verbal rating scales
for measurement of osteoarthritic knee pain. J Pain Res.
11:851–856. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carvalho JC, Thomas DG, McHugh JB, Shah RB
and Kunju LP: p63, CK7, PAX8 and INI-1: An optimal
immunohistochemical panel to distinguish poorly differentiated
urothelial cell carcinoma from high-grade tumours of the renal
collecting system. Histopathology. 60:597–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Higgins JP, Kaygusuz G, Wang L, Montgomery
K, Mason V, Zhu SX, Marinelli RJ, Presti JC Jr, van de Rijn M and
Brooks JD: Placental S100 (S100P) and GATA3: Markers for
transitional epithelium and urothelial carcinoma discovered by
complementary DNA microarray. Am J Surg Pathol. 31:673–680. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu H, Shi J, Wilkerson ML and Lin F:
Immunohistochemical evaluation of GATA3 expression in tumors and
normal tissues: A useful immunomarker for breast and urothelial
carcinomas. Am J Clin Pathol. 138:57–64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ordóñez NG: Value of GATA3 immunostaining
in tumor diagnosis: A review. Adv Anat Pathol. 20:352–360. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rana C, Babu S, Agarwal H, Singhai A,
Kumar M, Singh V, Sinha RJ and Shankhwar SN: Diagnostic relevance
of GATA 3 expression in urinary bladder carcinoma of divergent
differentiation and other histological variants. Indian J Surg
Oncol. 12:678–685. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rossi G, Pelosi G, Barbareschi M, Graziano
P, Cavazza A and Papotti M: Subtyping non-small cell lung cancer:
Relevant issues and operative recommendations for the best
pathology practice. Int J Surg Pathol. 21:326–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pelosi G, Rossi G, Cavazza A, Righi L,
Maisonneuve P, Barbareschi M, Graziano P, Pastorino U, Garassino M,
de Braud F and Papotti M: ΔNp63 (p40) distribution inside lung
cancer: A driver biomarker approach to tumor characterization. Int
J Surg Pathol. 21:229–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lam KY, Dickens P and Chan AC: Tumors of
the heart. A 20-year experience with a review of 12,485 consecutive
autopsies. Arch Pathol Lab Med. 117:1027–1031. 1993.PubMed/NCBI
|
|
16
|
Nakagawa K, Matsuno Y, Kunitoh H, Maeshima
A, Asamura H and Tsuchiya R: Immunohistochemical KIT (CD117)
expression in thymic epithelial tumors. Chest. 128:140–144. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Parent AD, Bebin J and Smith RR:
Incidental pituitary adenomas. J Neurosurg. 54:228–231. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu L, Dong Y, Xue J, Xu S, Wang G, Kuang D
and Duan Y: SOX11 is a sensitive and specific marker for pulmonary
high-grade neuroendocrine tumors. Diagn Pathol. 17:22022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He Y, Zhao L, Tang X, Jiang Q, Zhao X and
Cao Y: Prognostic implications of synaptophysin, CD56, thyroid
transcription factor-1, and Ki-67 in pulmonary high-grade
neuroendocrine carcinomas. Ann Diagn Pathol. 68:1522392024.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giudici N, Bonne F, Blarer J, Minoli M,
Krentel F and Seiler R: Characteristics of upper urinary tract
urothelial carcinoma in the context of bladder cancer: A narrative
review. Transl Androl Urol. 10:4036–4050. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu YH, Chou MH, Meng E and Kao CC: A rare
case report of metastatic urothelial carcinoma to skull with
significant reossification after pembrolizumab. Medicina (Kaunas).
57:9872021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stellato M, Santini D, Cursano MC,
Foderaro S, Tonini G and Procopio G: Bone metastases from
urothelial carcinoma. The dark side of the moon. J Bone Oncol.
31:1004052021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hiensch R, Belete H, Rashidfarokhi M,
Galperin I, Shakil F and Epelbaum O: Unusual patterns of thoracic
metastasis of urinary bladder carcinoma. J Clin Imaging Sci.
7:232017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ofri A and Moore K: Occult breast cancer:
Where are we at? Breast. 54:211–215. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen WH, Wang YH, Lu YC, Huang CC and Wong
SL: Endobronchial metastasis from an occult papillary thyroid
carcinoma: A case report. Changgeng Yi Xue Za Zhi. 21:200–205.
1998.PubMed/NCBI
|
|
27
|
Iguchi T, Wang CY, Delongchamps NB,
Sunheimer R, Nakatani T, de la Roza G and Haas GP: Occult prostate
cancer effects the results of case-control studies due to
verification bias. Anticancer Res. 28:3007–3010. 2008.PubMed/NCBI
|
|
28
|
Merseburger AS, Matuschek I and Kuczyk MA:
Bladder preserving strategies for muscle-invasive bladder cancer.
Curr Opin Urol. 18:513–518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galgano SJ, Porter KK, Burgan C and
Rais-Bahrami S: The role of imaging in bladder cancer diagnosis and
staging. Diagnostics (Basel). 10:7032020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mirmomen SM, Shinagare AB, Williams KE,
Silverman SG and Malayeri AA: Preoperative imaging for locoregional
staging of bladder cancer. Abdom Radiol (NY). 44:3843–3857. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee CH, Tan CH, Faria SC and Kundra V:
Role of imaging in the local staging of urothelial carcinoma of the
bladder. AJR Am J Roentgenol. 208:1193–1205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aydh A, Abufaraj M, Mori K, Quhal F,
Pradere B, Motlagh RS, Mostafaei H, Karakiewicz PI and Shariat SF:
Performance of fluoro-2-deoxy-D-glucose positron emission
tomography-computed tomography imaging for lymph node staging in
bladder and upper tract urothelial carcinoma: A systematic review.
Arab J Urol. 19:59–66. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kibel AS, Dehdashti F, Katz MD, Klim AP,
Grubb RL, Humphrey PA, Siegel C, Cao D, Gao F and Siegel BA:
Prospective study of [18F]fluorodeoxyglucose positron emission
tomography/computed tomography for staging of muscle-invasive
bladder carcinoma. J Clin Oncol. 27:4314–4320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Babjuk M, Böhle A, Burger M, Capoun O,
Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M,
et al: EAU Guidelines on non-muscle-invasive urothelial carcinoma
of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rafiemanesh H, Lotfi Z, Bakhtazad S,
Ghoncheh M and Salehiniya H: The epidemiological and histological
trend of bladder cancer in Iran. J Cancer Res Ther. 14:532–536.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bader MJ, Sroka R, Gratzke C, Seitz M,
Weidlich P, Staehler M, Becker A, Stief CG and Reich O: Laser
therapy for upper urinary tract transitional cell carcinoma:
Indications and management. Eur Urol. 56:65–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vicente-Rodriguez J, Chéchile G, Algaba F
and Amaral J Jr: Value of random endoscopic biopsy in the diagnosis
of bladder carcinoma in situ. Eur Urol. 13:150–152. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sakr SA, Abdel-Wahed MM and El-Sahra DG:
Immunohistochemical differential diagnosis between urothelial
carcinoma and prostate adenocarcinoma among Egyptian patients.
Biomed Pharmacother. 68:685–692. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim DH, Joo JE, Kim EK, Lee HJ and Lee WM:
The expressions of cytokeratin 7 and 20 in epithelial tumors: A
survey of 91 cases. Cancer Res Treat. 35:355–363. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chaux A, Han JS, Lee S, Gonzalez-Roibon N,
Sharma R, Burnett AL, Cubilla AL and Netto GJ: Immunohistochemical
profile of the penile urethra and differential expression of GATA3
in urothelial versus squamous cell carcinomas of the penile
urethra. Hum Pathol. 44:2760–2767. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Akhtar M, Rashid S, Gashir MB, Taha NM and
Al Bozom I: CK20 and CK5/6 immunohistochemical staining of
urothelial neoplasms: A perspective. Adv Urol. 2020:49202362020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kata SG and Aboumarzouk O: Are we closer
to seeing carcinoma in situ in the upper urinary tract? Cent
European J Urol. 69:157–161. 2016.PubMed/NCBI
|
|
43
|
Kim B, Garcia F, Touma N, Moussa M and
Izawa JI: A rare case of penile cancer in situ metastasizing to
lymph nodes. Can Urol Assoc J. 1:404–407. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Avrach WW and Christensen HE:
Metastasizing erythroplasia Queyrat. Report of a case. Acta Derm
Venereol. 56:409–412. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Eng TY, Petersen JP, Stack RS and Judson
PH: Lymph node metastasis from carcinoma in situ of the penis: A
case report. J Urol. 153:432–434. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Banys M, Hahn M, Gruber I, Krawczyk N,
Wallwiener M, Hartkopf A, Taran FA, Röhm C, Kurth R, Becker S, et
al: Detection and clinical relevance of hematogenous tumor cell
dissemination in patients with ductal carcinoma in situ. Breast
Cancer Res Treat. 144:531–538. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Narod SA and Sopik V: Is invasion a
necessary step for metastases in breast cancer? Breast Cancer Res
Treat. 169:9–23. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Klein CA: Parallel progression of primary
tumours and metastases. Nat Rev Cancer. 9:302–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang HY, Wu CY, Chen JJ and Lee TH:
Treatment strategies and metabolic pathway regulation in urothelial
cell carcinoma: A comprehensive review. Int J Mol Sci. 21:89932020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yuasa T, Urakami S and Yonese J: Recent
advances in medical therapy for metastatic urothelial cancer. Int J
Clin Oncol. 23:599–607. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rhea LP, Mendez-Marti S, Kim D and
Aragon-Ching JB: Role of immunotherapy in bladder cancer. Cancer
Treat Res Commun. 26:1002962021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ten Eyck JE, Kahlon N, Masih S, Hamouda DM
and Petros FG: Clinical evaluation of avelumab in the treatment of
advanced urothelial carcinoma: Focus on patient selection and
outcomes. Cancer Manag Res. 14:729–738. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tassinari E, Mollica V, Nuvola G,
Marchetti A, Rosellini M and Massari F: Treatment options for
metastatic urothelial carcinoma after first-line chemotherapy.
Cancer Manag Res. 14:1945–1960. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fenton SE and VanderWeele DJ:
Antibody-drug conjugates and predictive biomarkers in advanced
urothelial carcinoma. Front Oncol. 12:10693562023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Longo N, Celentano G, Napolitano L, La
Rocca R, Capece M, Califano G, Collà Ruvolo C, Mangiapia F, Fusco
F, Morra S, et al: Metastasis-directed radiation therapy with
consolidative intent for oligometastatic urothelial carcinoma: A
systematic review and meta-analysis. Cancers (Basel). 14:23732022.
View Article : Google Scholar : PubMed/NCBI
|
